Clinical trial
A Phase 3, Open-Label Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease
NCT00528840 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open-Label Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- October 31, 2008
- Enrollment
- 201 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
advanced dupuytren's disease